Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296475273> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4296475273 abstract "<h3>Introduction</h3> Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a life-changing treatment for people with cystic fibrosis (CF). Its use in liver transplant recipients needs to be carefully assessed due to possible worsening of liver function tests (LFTs) and interactions with immunosuppressive treatment. We report our initial experience of ELX/TEZ/IVA in liver transplant recipients. <h3>Methods</h3> A retrospective review of clinical, biochemical, and histological data for adult liver transplant recipients receiving ELX/TEZ/IVA treatment was undertaken. All were attending the Leeds adult regional CF Centre and under regular review by the joint liver and CF multidisciplinary team. <h3>Results</h3> Four post liver transplant recipients (3 Male F/F, 1 female F/MF, age 18–45 y, median baseline FEV1 51.5 [31–72]%) had been started on ELX/TEZ/IVA. Median time from transplant was 6.5 [2–12] years. Treatment resulted in improved FEV1 (relative increase 22 (10–30)%), reduction in IV antibiotics requirement and sweat chloride concentration (median drop 50 (20–71) mmol/l) in all subjects. One subject (F, 42y) had no liver-related side effects and did not require tacrolimus dose adjustment. All male patients experienced increase in LFTs (max ALT 108–180 iU/L, max bilirubin 30–57 umol/L) within the first two months of treatment and underwent liver biopsy. In two cases, histopathology revealed unremarkable liver parenchyma and absence of drug-induced liver injury or rejection. In the third case, peri-venulitis, marked inflammation and mild fibrosis were identified and thought to reflect worsening features of a previously identified immuno-mediated pathology, requiring temporarily suspension of ELX/TEZ/IVA and augmented immunosuppression. The latter subject is now back on treatment and remains stable. <h3>Conclusion</h3> In our small cohort, ELX/TEZ/IVA caused acute derangement in LFTs in liver transplant recipients. Liver biopsy, reassuringly, showed no features of drug-induced liver injury." @default.
- W4296475273 created "2022-09-21" @default.
- W4296475273 creator A5005368828 @default.
- W4296475273 creator A5036324531 @default.
- W4296475273 creator A5041527005 @default.
- W4296475273 creator A5054837162 @default.
- W4296475273 creator A5088801314 @default.
- W4296475273 date "2022-09-01" @default.
- W4296475273 modified "2023-10-12" @default.
- W4296475273 title "OP31 Can liver biopsy guide the management of deranged liver function tests in liver transplant recipients receiving Kaftrio?" @default.
- W4296475273 doi "https://doi.org/10.1136/gutjnl-2022-basl.44" @default.
- W4296475273 hasPublicationYear "2022" @default.
- W4296475273 type Work @default.
- W4296475273 citedByCount "0" @default.
- W4296475273 crossrefType "proceedings-article" @default.
- W4296475273 hasAuthorship W4296475273A5005368828 @default.
- W4296475273 hasAuthorship W4296475273A5036324531 @default.
- W4296475273 hasAuthorship W4296475273A5041527005 @default.
- W4296475273 hasAuthorship W4296475273A5054837162 @default.
- W4296475273 hasAuthorship W4296475273A5088801314 @default.
- W4296475273 hasConcept C126322002 @default.
- W4296475273 hasConcept C142724271 @default.
- W4296475273 hasConcept C2775934546 @default.
- W4296475273 hasConcept C2777513400 @default.
- W4296475273 hasConcept C2777766500 @default.
- W4296475273 hasConcept C2779609443 @default.
- W4296475273 hasConcept C2909675724 @default.
- W4296475273 hasConcept C2911091166 @default.
- W4296475273 hasConcept C2992208098 @default.
- W4296475273 hasConcept C512861765 @default.
- W4296475273 hasConcept C544855455 @default.
- W4296475273 hasConcept C71924100 @default.
- W4296475273 hasConcept C90924648 @default.
- W4296475273 hasConceptScore W4296475273C126322002 @default.
- W4296475273 hasConceptScore W4296475273C142724271 @default.
- W4296475273 hasConceptScore W4296475273C2775934546 @default.
- W4296475273 hasConceptScore W4296475273C2777513400 @default.
- W4296475273 hasConceptScore W4296475273C2777766500 @default.
- W4296475273 hasConceptScore W4296475273C2779609443 @default.
- W4296475273 hasConceptScore W4296475273C2909675724 @default.
- W4296475273 hasConceptScore W4296475273C2911091166 @default.
- W4296475273 hasConceptScore W4296475273C2992208098 @default.
- W4296475273 hasConceptScore W4296475273C512861765 @default.
- W4296475273 hasConceptScore W4296475273C544855455 @default.
- W4296475273 hasConceptScore W4296475273C71924100 @default.
- W4296475273 hasConceptScore W4296475273C90924648 @default.
- W4296475273 hasLocation W42964752731 @default.
- W4296475273 hasOpenAccess W4296475273 @default.
- W4296475273 hasPrimaryLocation W42964752731 @default.
- W4296475273 hasRelatedWork W172594671 @default.
- W4296475273 hasRelatedWork W2021351174 @default.
- W4296475273 hasRelatedWork W2079281353 @default.
- W4296475273 hasRelatedWork W2352212115 @default.
- W4296475273 hasRelatedWork W2383422223 @default.
- W4296475273 hasRelatedWork W2388800377 @default.
- W4296475273 hasRelatedWork W2408736641 @default.
- W4296475273 hasRelatedWork W2792898665 @default.
- W4296475273 hasRelatedWork W3030746140 @default.
- W4296475273 hasRelatedWork W3031392551 @default.
- W4296475273 isParatext "false" @default.
- W4296475273 isRetracted "false" @default.
- W4296475273 workType "article" @default.